Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients

Abstract

Haloperidol serum concentrations were determined after IM or oral treatment in 15 schizophrenic patients. No correlation was found between drug levels and therapeutic effect. However, a good relationship was found between the half-life calculated after the first IM injection and the BPRS decrease after 3 weeks. Therefore a serum level study on the first day may forecast the therapeutic response.

This is a preview of subscription content, log in to check access.

References

  1. Bjorndal N, Bjerre M, Gerlach J, Kristiansen P, Magelund G, Oestrich IH, Waehrens J (1980) High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response side effects, serum haloperidol and serum prolactin. Psychopharmacology 67:17–23

  2. Clark ML, Kaul PN (1976) A preliminary report on clinical response and blood levels of chlorpromazine and its sulfoxide during chlorpromazine therapy in chronic schizophrenic patients. In: Gottschalk and Merlis (eds) Pharmacokinetics of psychoactive drugs: Blood levels and clinical response. Spectrum, New York, pp 191–197

  3. Cressman WA, Bianchine JR, Slotnick VB, Johnson PC, Plostnieks J (1974) Plasma level profile of haloperidol in man following intramuscular administration. Eur J Clin Pharmacol 7:99–103

  4. Davy JP (1979) Relation des taux des neuroleptiques avec les doses, les actions thérapeutiques et les effects secondaires. Mémoire pour le C.E.S. de Psychiatrie, pp 55–163

  5. Forsman A, Martensson E, Nyberg G, Ohman R (1974) A gas chromatographic method for determining haloperidol. Arch Pharmacol 286:113–124

  6. Forsman A, Ohman R (1974) On the pharmacokinetics of haloperidol. Nord Psyk Tidsskr 28:441–448

  7. Forsman A, Ohman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res 20:319–336

  8. Forsman A, Fölsch G, Larson M, Ohman R (1977) On the metabolism of haloperidol in man. Curr Ther Res 21:606–661

  9. Forsman A, Ohman R (1977) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396–408

  10. Gottschalk LA, Biener R, Noble EP, Birch H, Wilbert DE, Heiser JF (1975) Thioridazine plasma levels and clinical response. Compr Psychiatry 16:323–337

  11. Morselli PL, Zarifian E, Cuche M, Bianchetti G, Cotterau MJ, Denicker P (1980) Haloperidol plasma level monitoring in psychiatric patients. Long term effect of neuroleptics. Adv Biochem Psychopharmacol 24:529–536

  12. Moulin M, Camsonne R, Debruyne D, Bigot MC, Davy JP, Morel P, Poilpré E (1979) Relations entre taux sanguins des neuroleptiques et effets cliniques. 1-er Colloque Franco-Japonais de Psychopharmacologie, Paris, 4–6 octobre (INSERM ed), pp 371–384

  13. Takahashi R, Yoshimoto S, Matsumoto H (1979) Implication of plasma level of neuroleptics in the treatment and pathophysiological research of schizophrenia, 1-er Colloque Eranco-Japonais de Psychopharmacologie, Paris, 4–6 octobre (INSERM ed), pp 337–370

  14. Zingales IA (1971) A gas chromatographic method for the determination of haloperidol in human plasma. J Chromatogr 54:15–24

Download references

Author information

Correspondence to M. A. Moulin.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Moulin, M.A., Davy, J.P., Debruyne, D. et al. Serum level monitoring and therapeutic effect of haloperidol in schizophrenic patients. Psychopharmacology 76, 346–350 (1982). https://doi.org/10.1007/BF00449123

Download citation

Key words

  • Schizophrenia
  • Haloperidol
  • Serum levels